Pharma Sales at Risk? $3.6B Medicare Subsidy Cut Could Hit 2027 Adherence

For biopharma companies, the sunset of the Part D premium subsidy, coupled with ongoing drug price negotiations, creates a more challenging access environment in the Medicare market, where even modest cost-sharing increases can deter chronic medication use among fixed-income patients. This policy shift demands a reassessment of patient affordability programs and market forecast models for 2027.

The Trump administration's Centers for Medicare & Medicaid Services (CMS) this week announced the conclusion of a temporary Medicare Part D subsidy program, a move that could raise monthly prescription drug premiums for roughly 25 million beneficiaries starting in 2027. The subsidy, originally implemented by the Biden administration in 2024, was designed to cushion seniors from sharp premium increases triggered by the 2022 Inflation Reduction Act (IRA). Its termination comes just as the first wave of IRA-mandated drug price cuts—lowering costs for 10 of Part D's most expensive medications—is set to take effect in January 2026, creating a complex and politically charged landscape for older Americans’ medication costs.

“

Mehmet Oz as a necessary fiscal step, preventing an estimated $3.6 billion in 2026 alone from flowing to insurance companies as subsidy payments.

The program's end was rationalized by CMS Administrator Dr. Mehmet Oz as a necessary fiscal step, preventing an estimated $3.6 billion in 2026 alone from flowing to insurance companies as subsidy payments. While federal officials insist the financial impact on beneficiaries will be minimal, the timing could not be more precarious. The roughly 25 million Americans enrolled in Part D plans are predominantly on fixed incomes, and even modest premium increases can strain budgets, forcing difficult trade-offs between prescriptions and other essentials. The IRA itself had redesigned the Part D benefit structure, capping out-of-pocket costs but inadvertently raising base premiums; the temporary subsidy had absorbed that shock, and its removal now shifts costs back onto enrollees.

Politically, the decision becomes instant fodder in a high-stakes midterm election year where cost of living remains voters’ overriding concern. Senate Minority Leader Chuck Schumer lambasted the move, calling it “heartless, cruel, and completely by choice,” and framing it alongside other Republican-led healthcare rollbacks, such as federal Medicaid cuts and the expiration of Affordable Care Act subsidies for working-age individuals. The administration counters that the subsidy was always temporary and that continuing it would effectively funnel taxpayer dollars to insurers rather than patients. Yet, with 2027 premium rates set to be announced in the fall of 2026—just as voters head to the polls—any perceptible hike could carry outsized political consequences, particularly given seniors' historically high turnout.

From a market standpoint, ending the subsidy introduces new dynamics for insurers and pharmaceutical manufacturers alike. Insurers will need to recalibrate their bids for 2027 without the cushion of federal subsidy dollars, potentially raising premiums or reducing benefit generosity. For drug companies, the expiration adds another affordability hurdle alongside the IRA's direct price negotiations, which are already compressing margins on high-revenue Medicare drugs. If higher premiums lead to reduced adherence—a well-documented consequence of even small cost-sharing increases among seniors—pharmaceutical sales volumes in the lucrative Part D channel could soften, amplifying the IRA’s downward pressure on industry revenues.